Winner Medical(SZ:300888) Sou Hu Cai Jing·2025-12-23 14:50Core Viewpoint - The company Steady Medical (300888) has shown significant growth in its financial performance for the first three quarters of 2025, with a notable increase in revenue and net profit compared to the previous year [2]. Financial Performance - For the first three quarters of 2025, Steady Medical reported a total revenue of 7.897 billion yuan, representing a year-on-year increase of 30.1% [2]. - The net profit attributable to shareholders reached 732 million yuan, up 32.36% year-on-year [2]. - The company's net profit excluding non-recurring items was 679 million yuan, reflecting a 43.93% increase year-on-year [2]. - In Q3 2025 alone, the company achieved a revenue of 2.601 billion yuan, which is a 27.71% increase compared to the same quarter last year [2]. - The net profit for Q3 2025 was 240 million yuan, marking a 42.11% year-on-year growth [2]. - The net profit excluding non-recurring items for Q3 2025 was 218 million yuan, showing a 50.77% increase year-on-year [2]. - The company's debt ratio stands at 33.87%, with investment income of 33.23 million yuan and financial expenses of -2.036 million yuan [2]. - The gross profit margin is reported at 48.32% [2]. Market Activity - As of December 23, 2025, Steady Medical's stock closed at 38.23 yuan, down 0.78% with a turnover rate of 0.35% [1]. - The trading volume was 20,300 hands, with a total transaction value of 77.6143 million yuan [1]. - On December 23, the net inflow of main funds was 4.874 million yuan, accounting for 6.28% of the total transaction value, while retail funds saw a net inflow of 3.3709 million yuan, making up 4.34% [1]. Analyst Ratings - In the last 90 days, 20 institutions have provided ratings for Steady Medical, with 17 buy ratings and 3 hold ratings [2]. - The average target price set by institutions over the past 90 days is 5.488 billion yuan [2].